News

Perceptive neurologists have discovered a new type of vertigo. So far, the cause is unknown, though treatment seems to be effective.

What are the best available options for patients with CIDP, and what is still missing?

The Director of the Movement Disorders Clinic at the University of Louisville emphasized the importance of knowing each patient, where they’re coming from and their goals.

A subcutaneous intrathecal catheter delivery system has proven safe and tolerable in a preliminary investigation in patients with SMA.

The director of the ALS Clinic at Massachusetts General Hospital pointed to the robust pipeline and meaningful gains in knowledge about the disease as reason to be hopeful.

The director of the Movement Disorders Clinic at University of Louisville spoke about current therapies available for patients but stressed that they often don’t address the non-motor features.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia said that for these patients, there are still many questions without answers.

How did erenumab's approval by the FDA change the landscape of migraine treatment?

The VMAT2 inhibitor showed improvements through 48 weeks, though after halting therapy, some loss of improvement was observed.

The director of the Pediatric Headache Program at Children’s Hospital of Philadelphia spoke about the potential for CGRP inhibitors to find use in pediatric patients.

The COMT inhibitor resulted in 65-minute and 39-minute decreases in mean off time for patients who switched from placebo and entacapone, respectively.

Can this first-of-its-kind guideline for identifying biomarkers in Parkinson disease invigorate a drive for disease-modifying therapy development?

Results concluded that noninvasive OCT was able to detect significant thinning especially in the center of the retina, around the fovea, in the inner layers of the retina prior to any evidence of dementia.

The mesenchymal stem cell therapy passed an interim safety analysis for the first 31 patients with amyotrophic lateral sclerosis.

The Clinical Director of the Brain Donation Program at Cleveland Clinic’s Mellen Center for Treatment and Research in MS provided some insight into the consequences of this discovery.

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.

Lutz Frölich, MD, PhD, provides a look at BI409306, a novel selective PDE9A inhibitor, and how the negative results of its phase II trial can inform the community.

tDCS has been shown to be easily applicable, without significant adverse effects and relatively low-cost compared other pharmacologic treatments.

The Department Chair of Neurosciences at Cleveland Clinic was a leading part of the group of researchers that recently identified the new subtype of multiple sclerosis.

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

Darin Okuda, MD, spoke about the new investigative therapies for MS, as well as the expanding role of disease-modifying therapies.

What is known about chronic inflammatory demyelinating polyradiculoneuropathy, a neurological disorder marked by by progressive weakness and impaired sensory function in the extremeties?

Investigators have identified a new subtype of MS in postmortem tissue, characterized by a lack of cerebral white matter demyelination.

The designation is backed by positive interim data from ASPIRO, which has demonstrated significant improvements in neuromuscular and respiratory function at week 24.

The approval is backed by the effectiveness established in 2, 12-week studies in patients with Dravet syndrome, and open-label long-term studies.

Patients treated with fludrocortisone normalized their serum sodium levels in only 4 days—significantly quicker than saline alone, which took 15 days.

Patients administered A-tDCS during outpatient speech therapy were shown to have a relative increase of 70% in correct-naming for A-tDCS compared to sham.

Several clinical trials are examining the role of stem cells, inflammation, and other pathways in ALS.